James S. Wilmott

68.1k citations

139 papers · 6.4k indexed · 3 hit papers · h-index 36

Oncology top 0.5%
Molecular Biology top 2%
Immunology top 1%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 2%

Co-authors: Richard A. Scolyer Georgina V. Long John F. Thompson Alexander M. Menzies Richard Kefford Peter Hersey Tuba N. Gide Hojabr Kakavand
Topics: Cancer Immunotherapy and Biomarkers (57 papers)Immunotherapy and Immune Responses (48 papers)Melanoma and MAPK Pathways (47 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Nature Communications
Partner nations: Australia United States Netherlands

In The Last Decade

James S. Wilmott

130 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Serigne Lo et al. profile →
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

2011 507 citations James S. Wilmott, Georgina V. Long et al. Clinical Cancer Research profile →
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by James S. Wilmott

Since Specialization

Citations

This map shows the geographic impact of James S. Wilmott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James S. Wilmott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James S. Wilmott more than expected).

Fields of papers citing papers by James S. Wilmott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James S. Wilmott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James S. Wilmott. The network helps show where James S. Wilmott may publish in the future.

Co-authorship network of co-authors of James S. Wilmott

This figure shows the co-authorship network connecting the top 25 collaborators of James S. Wilmott. A scholar is included among the top collaborators of James S. Wilmott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James S. Wilmott. James S. Wilmott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma 2024 ·Clinical Cancer Research ·Tuba N. Gide,(unknown),Richard A. Scolyer,Georgina V. Long,James S. Wilmott	1
2	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach 2023 ·Journal of Translational Medicine ·(unknown),Tuba N. Gide,Nurudeen A. Adegoke,Camelia Quek,(unknown),Alison J. Potter,Ellis Patrick,Robyn P.M. Saw,John F. Thompson,Andrew J. Spillane,Kerwin F. Shannon,Matteo S. Carlino,Serigne Lo,Alexander M. Menzies,Inês Pires da Silva,Georgina V. Long,Richard A. Scolyer,James S. Wilmott	6
3	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis 2022 ·JCI Insight ·(unknown),Felix Marsh‐Wakefield,Robert V. Rawson,Tuba N. Gide,Angela L. Ferguson,(unknown),Camelia Quek,Inês Pires da Silva,(unknown),(unknown),Neomal S. Sandanayake,Matteo S. Carlino,Geoffrey W. McCaughan,James S. Wilmott,Richard A. Scolyer,Georgina V. Long,Alexander M. Menzies,Umaimainthan Palendira	10
4	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma 2021 ·Clinical Cancer Research ·Greg Kelly,Fares Al‐Ejeh,Robert McCuaig,Francesco Casciello,(unknown),Blake Ferguson,Antonia L. Pritchard,Sayed Ali,Inês Pires da Silva,James S. Wilmott,Georgina V. Long,Richard A. Scolyer,Sudha Rao,Nicholas K. Hayward,Frank Gannon,Jason S. Lee	29
5	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition 2020 ·Nature Communications ·Jenny Lee,Elena Shklovskaya,Su Yin Lim,Matteo S. Carlino,Alexander M. Menzies,Ashleigh Stewart,Bernadette Pedersen,(unknown),Sara Alavi,Jean Yang,Dario Strbenac,Robyn P.M. Saw,John F. Thompson,James S. Wilmott,Richard A. Scolyer,Georgina V. Long,Richard Kefford,Helen Rizos	193
6	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model 2020 ·PLoS ONE ·Kelly J. McKelvey,Amanda L. Hudson,(unknown),James S. Wilmott,Grace H. Attrill,Georgina V. Long,Richard A. Scolyer,Stephen Clarke,Helen Wheeler,Connie I. Diakos,Viive M. Howell	19
7	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials 2019 ·Clinical Cancer Research ·Jarem Edwards,Annie Tasker,Inês Pires da Silva,Camelia Quek,Marcel Batten,Angela L. Ferguson,(unknown),(unknown),Robyn P.M. Saw,John F. Thompson,Alexander M. Menzies,Umaimainthan Palendira,James S. Wilmott,Georgina V. Long,Richard A. Scolyer	26
8	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockadebreakdown → 2019 ·Clinical Cancer Research ·Imran G. House,Peter Savas,Junyun Lai,Amanda X. Y. Chen,Amanda J. Oliver,Zhi L. Teo,Kirsten L. Todd,Melissa A. Henderson,Lauren Giuffrida,Emma V. Petley,Kevin Sek,Sherly Mardiana,Tuba N. Gide,Camelia Quek,Richard A. Scolyer,Georgina V. Long,James S. Wilmott,Sherene Loi,Phillip K. Darcy,Paul A. Beavis	412
9	LNK suppresses interferon signaling in melanoma 2019 ·Nature Communications ·Ling‐Wen Ding,Qiao‐Yang Sun,Jarem Edwards,Lucia Torres Fernández,(unknown),Siqin Zhou,Richard A. Scolyer,James S. Wilmott,John F. Thompson,Ngan Doan,Jonathan Said,(unknown),Jin-Fen Xiao,(unknown),Maren Pein,Liang Xu,David W. Mullins,Henry Yang,De‐Chen Lin,H. Phillip Koeffler	20
10	bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays 2018 ·Bioinformatics ·Kevin Wang,Alexander M. Menzies,Inês Pires da Silva,James S. Wilmott,Yibing Yan,Matthew Wongchenko,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Garth Tarr,(unknown),Jean Yang	1
11	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment 2018 ·Clinical Cancer Research ·Jarem Edwards,James S. Wilmott,Jason Madore,Tuba N. Gide,Camelia Quek,Annie Tasker,Angela L. Ferguson,Jinbiao Chen,Rehana Hewavisenti,Peter Hersey,Thomas Gebhardt,Wolfgang Weninger,Warwick J. Britton,Robyn P.M. Saw,John F. Thompson,Alexander M. Menzies,Georgina V. Long,Richard A. Scolyer,Umaimainthan Palendira	317
12	Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress 2017 ·Cancer Research ·(unknown),Guangzhi Liu,James S. Wilmott,Ting La,Yuchen Feng,Hamed Yari,Xu Guang Yan,Rick F. Thorne,Richard A. Scolyer,Xu Dong Zhang,Lei Jin	41
13	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma 2017 ·Clinical Cancer Research ·Tuba N. Gide,James S. Wilmott,Richard A. Scolyer,Georgina V. Long	313
14	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma 2017 ·Clinical Cancer Research ·Ricardo E. Vilain,Alexander M. Menzies,James S. Wilmott,Hojabr Kakavand,Jason Madore,Alexander Guminski,Elizabeth Liniker,Benjamin Y. Kong,Adam Cooper,Julie R. Howle,Robyn P.M. Saw,Valerie Jakrot,Serigne Lo,John F. Thompson,Matteo S. Carlino,Richard Kefford,Georgina V. Long,Richard A. Scolyer	191
15	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors 2017 ·Clinical Cancer Research ·Hojabr Kakavand,Robert V. Rawson,Gulietta M. Pupo,Jean Yang,Alexander M. Menzies,Matteo S. Carlino,Richard Kefford,Julie R. Howle,Robyn P.M. Saw,John F. Thompson,James S. Wilmott,Georgina V. Long,Richard A. Scolyer,Helen Rizos	63
16	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma 2016 ·Clinical Cancer Research ·Jason Madore,Dario Strbenac,Ricardo E. Vilain,Alexander M. Menzies,Jean Yang,John F. Thompson,Georgina V. Long,Graham J. Mann,Richard A. Scolyer,James S. Wilmott	92
17	RIP1 Kinase Is an Oncogenic Driver in Melanoma 2015 ·Cancer Research ·Xiao Ying Liu,Fritz Lai,Xu Guang Yan,Chen Chen Jiang,Su Guo,Chunyan Wang,Amanda Croft,Hsin‐Yi Tseng,James S. Wilmott,Richard A. Scolyer,Lei Jin,Xu Dong Zhang	58
18	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients 2015 ·Clinical Cancer Research ·Hojabr Kakavand,James S. Wilmott,Alexander M. Menzies,Ricardo E. Vilain,Lauren E. Haydu,Jennifer H. Yearley,John F. Thompson,Richard Kefford,Peter Hersey,Georgina V. Long,Richard A. Scolyer	115
19	PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials 2014 ·Pigment Cell & Melanoma Research ·Jason Madore,Ricardo E. Vilain,Alexander M. Menzies,Hojabr Kakavand,James S. Wilmott,Jessica Hyman,Jennifer H. Yearley,Richard Kefford,John F. Thompson,Georgina V. Long,Peter Hersey,Richard A. Scolyer	333
20	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanomabreakdown → 2011 ·Clinical Cancer Research ·James S. Wilmott,Georgina V. Long,Julie R. Howle,Lauren E. Haydu,Raghwa Sharma,John F. Thompson,Richard Kefford,Peter Hersey,Richard A. Scolyer	507

About James S. Wilmott

James S. Wilmott is a scholar working on Oncology, Immunology and Cancer Research, having authored 139 papers that have together received 6.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (57 papers), Immunotherapy and Immune Responses (48 papers) and Melanoma and MAPK Pathways (47 papers). The work is most often cited by research in Oncology (4.4k citations), Immunology (2.4k citations) and Cancer Research (798 citations). James S. Wilmott has collaborated with scholars based in Australia, United States and Netherlands. Frequent co-authors include Richard A. Scolyer, Georgina V. Long, John F. Thompson, Alexander M. Menzies, Richard Kefford, Peter Hersey, Tuba N. Gide, Hojabr Kakavand, Lauren E. Haydu and Serigne Lo. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact